and multiple [7] iStent devices during cataract surgery, and with multiple iStent devices as a standalone procedure [8] [9] [10] [11] .
More recent years have brought the advent of second-generation trabecular micro-bypass stents (iStent inject Ò Trabecular Micro-Bypass, Glaukos Corporation, San Clemente, CA, USA). Several studies have demonstrated substantial IOP and medication reduction following implantation of 2 iStent inject devices during cataract surgery [12] or in standalone procedures [13] [14] [15] [16] . In addition to their clinical effectiveness, these devices have shown a favorable safety profile, which is an important advantage over traditional surgeries such as trabeculectomy or tube placement, or more recently developed suprachoroidal stents [17, 18] .
In the present study, we tested the hypothesis that IOP and medication burden would be reduced following the standalone implantation of 2 second-generation iStent obtained from all patients for being included in the study. The ClinicalTrials.gov registration number for this study is NCT02868190.
As described previously in detail [12] [13] [14] [15] , the second-generation iStent inject device is a single-piece, titanium, heparin-coated stent with 360 lm length, 230 lm maximum width, and multiple lateral outlet lumens to facilitate aqueous fluid outflow ( Fig. 1 
RESULTS

Subject Accountability, Demographics and Pre-Study Parameters
A total of 57 qualified subjects underwent ab interno implantation of 2 iStent inject devices in a standalone procedure (i.e., without cataract surgery). Fig. 4) . The mean C:D ratio, visual field mean deviation and pattern standard deviation, and central corneal thickness also remained stable over the 18-month follow-up ( [3] [4] [5] [6] and multiple [7] first-generation stents (iStent) during cataract surgery; multiple first-generation stents as a standalone procedure [8] [9] [10] [11] ; and two second-generation stents (iStent inject) either with [12] or without cataract surgery in OAG patients with moderate IOP elevation and/or medication burden [13] [14] [15] [16] . In the present study, the observed IOP reduction of 10.2 mmHg was similar to the 7.0-10.5 mmHg reduction observed in these earlier studies of standalone iStent inject implantation in phakic eyes with OAG [13] [14] [15] [16] . The present study analyzes IOP and medication use after standalone iStent inject implantation in phakic OAG eyes with IOP not managed to below 18 mmHg on 1 preoperative medication. Thus, the findings shed light on the utility of these stents in a relatively early stage of managing the disease.
The reduction in medication-free IOP supports the independent effect of second-generation trabecular micro-bypass stents without the confounding factors of concomitant cataract surgery or medication use. Perhaps even more meaningful, subjects' postoperative IOP was 27% lower without medications 18 months after receiving 2 iStent inject devices than with medication before surgery. The elimination of medication represents a benefit in terms of both cost [19] and compliance [20] [21] [22] [23] to glaucoma patients, most of whom have at least one other chronic condition demanding their funds and attention [24] . Indeed, an inherent advantage of ab interno trabecular bypass stents over medications is reduced dependence on medication compliance, which theoretically may increase long-term treatment success.
Safety outcomes were favorable through the 18 months of follow-up, with only 1 postoperative adverse event (BCVA loss due to cataract progression; cataract surgery has been planned) and no intraoperative or device-related adverse events. Furthermore, the study's involvement of multiple surgeons offers external validation of safety of the implantation technique. This favorable safety profile is consistent with that observed in previous studies of iStent inject in subjects with mild to moderate primary OAG [12] [13] [14] [15] [16] . One additional medication was started in 1 eye at 18 months (IOP was 17.7 mmHg), but all remaining eyes remained medication-free, and no eyes underwent secondary surgery. Subject accountability was 100% through 18 months, supporting the validity of the study's findings. 
CONCLUSIONS
This study collected valuable data in a stable cohort with excellent accountability through 18 months, and follow-up is ongoing. The results confirm that IOP reduction to B15 mmHg with elimination of medicationand a favorable safety profile-is possible after the standalone implantation of two iStent inject devices in OAG eyes with IOP not managed to below 18 mmHg on 1 preoperative medication.
In light of this positive benefit-to-risk profile, as well as the well-known issues with compliance, cost, and side effects associated with topical medications, this microsurgical technique may constitute a desirable alternative for these patients with earlier stages of OAG.
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